---
title: "Seaport, Hemab launch US IPOs as biotech listings gather momentum"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284221810.md"
description: "April 27 (Reuters) - Drug developers Seaport Therapeutics and Hemab Therapeutics launched their U.S. initial public offerings on Monday, seeking to capitalize on a growing investor appetite for new listings. The U.S. IPO market has regained momentum this month, as improving risk appetite and stronger investor sentiment encourage companies across sectors to pursue listings, despite the risks a"
datetime: "2026-04-27T13:03:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284221810.md)
  - [en](https://longbridge.com/en/news/284221810.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284221810.md)
---

# Seaport, Hemab launch US IPOs as biotech listings gather momentum

April 27 (Reuters) - Drug developers Seaport Therapeutics and Hemab Therapeutics launched their U.S. initial public offerings on Monday, seeking to capitalize on a growing investor appetite for new listings. The U.S. IPO market has regained momentum this month, as improving risk appetite and stronger investor sentiment encourage companies across sectors to pursue listings, despite the risks a

### Related Stocks

- [SEEL.US](https://longbridge.com/en/quote/SEEL.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)